Skip to main content
Top
Published in: Inflammation 2/2019

01-04-2019 | Acute Respiratory Distress-Syndrome | ORIGINAL ARTICLE

Umbelliferone Alleviates Lipopolysaccharide-Induced Inflammatory Responses in Acute Lung Injury by Down-Regulating TLR4/MyD88/NF-κB Signaling

Authors: Dongqiu Wang, Xia Wang, Wen Tong, Yuhong Cui, Xiuxian Li, Haiyun Sun

Published in: Inflammation | Issue 2/2019

Login to get access

Abstract

This study investigated the protective effect and underlying mechanism of action of umbelliferone (Umb) against lipopolysaccharide (LPS)-induced acute lung injury (ALI). An intragastric Umb injection prior to the administration of LPS dramatically decreased the wet/dry lung weight ratio, attenuated inflammatory cell infiltration in lung tissue, and reduced the LPS-induced production of inflammatory cytokines, including monocyte chemotactic protein-1(MCP-1), interleukin (IL)-6, tumor necrosis factor-α (TNF-α), and IL-1β, in broncheoalveolar lavage fluid (BALF). In addition, Umb resulted in significant anti-oxidative effects as shown by decreased myeloperoxidase (MPO) and malondialdehyde (MDA) activity and increased superoxide dismutase (SOD) activity compared with the LPS group. Finally, the inhibitory effects of Umb on the expression of toll-like receptor 4 (TLR4)/myeloid differentiation protein 88 (MyD88)/nuclear factor-κB (NF-κB) signaling pathway proteins were also measured. Our results clearly indicated that Umb exerted significant protective effects on LPS-induced ALI by inhibiting the activation of the TLR4/MyD88/NF-κB pathway.
Literature
3.
go back to reference Banerji, N., M. Maiti, S. Sem, and P.C. Datta. 1982. Pharmacognosy of Aegle marmelos (L) Correa. seed. A new protein source. Acta Pharm Hung 52 (3): 97–101.PubMed Banerji, N., M. Maiti, S. Sem, and P.C. Datta. 1982. Pharmacognosy of Aegle marmelos (L) Correa. seed. A new protein source. Acta Pharm Hung 52 (3): 97–101.PubMed
12.
go back to reference Hoult, J.R., and M. Paya. 1996. Pharmacological and biochemical actions of simple coumarins: Natural products with therapeutic potential. General Pharmacology 27 (4): 713–722.CrossRefPubMed Hoult, J.R., and M. Paya. 1996. Pharmacological and biochemical actions of simple coumarins: Natural products with therapeutic potential. General Pharmacology 27 (4): 713–722.CrossRefPubMed
15.
go back to reference Jobin, C., C.A. Bradham, M.P. Russo, B. Juma, A.S. Narula, D.A. Brenner, and R.B. Sartor. 1999. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. Journal of Immunology 163 (6): 3474–3483. Jobin, C., C.A. Bradham, M.P. Russo, B. Juma, A.S. Narula, D.A. Brenner, and R.B. Sartor. 1999. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. Journal of Immunology 163 (6): 3474–3483.
18.
26.
go back to reference Newman, David J., and Gordon M. Cragg. 2007. Natural products as sources of new drugs over the last 25 years. Journal of Natural Products 70 (3): 461–477.CrossRefPubMed Newman, David J., and Gordon M. Cragg. 2007. Natural products as sources of new drugs over the last 25 years. Journal of Natural Products 70 (3): 461–477.CrossRefPubMed
28.
go back to reference Pillai, S.P., S.R. Menon, L.A. Mitscher, C.A. Pillai, and D.M. Shankel. 1999. Umbelliferone analogues and their potential to inhibit benzo(a)pyrene- and hydrogen peroxide-induced mutations. Journal of Natural Products 62 (10): 1358–1362.CrossRefPubMed Pillai, S.P., S.R. Menon, L.A. Mitscher, C.A. Pillai, and D.M. Shankel. 1999. Umbelliferone analogues and their potential to inhibit benzo(a)pyrene- and hydrogen peroxide-induced mutations. Journal of Natural Products 62 (10): 1358–1362.CrossRefPubMed
36.
go back to reference Worthen, G.S., C. Haslett, A.J. Rees, R.S. Gumbay, J.E. Henson, and P.M. Henson. 1987. Neutrophil-Mediated Pulmonary Vascular Injury - Synergistic Effect Of Trace Amounts Of Lipopolysaccharide And Neutrophil Stimuli on Vascular-Permeability And Neutrophil Sequestration In the Lung. American Review Of Respiratory Disease 136 (1): 19–28. https://doi.org/10.1164/ajrccm/136.1.19.CrossRefPubMed Worthen, G.S., C. Haslett, A.J. Rees, R.S. Gumbay, J.E. Henson, and P.M. Henson. 1987. Neutrophil-Mediated Pulmonary Vascular Injury - Synergistic Effect Of Trace Amounts Of Lipopolysaccharide And Neutrophil Stimuli on Vascular-Permeability And Neutrophil Sequestration In the Lung. American Review Of Respiratory Disease 136 (1): 19–28. https://​doi.​org/​10.​1164/​ajrccm/​136.​1.​19.CrossRefPubMed
Metadata
Title
Umbelliferone Alleviates Lipopolysaccharide-Induced Inflammatory Responses in Acute Lung Injury by Down-Regulating TLR4/MyD88/NF-κB Signaling
Authors
Dongqiu Wang
Xia Wang
Wen Tong
Yuhong Cui
Xiuxian Li
Haiyun Sun
Publication date
01-04-2019
Publisher
Springer US
Published in
Inflammation / Issue 2/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-018-00953-4

Other articles of this Issue 2/2019

Inflammation 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.